These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6303106)

  • 1. Lack of potentiation of vincristine-induced neurotoxicity by VP-16-213.
    Jackson DV; Wells HB; White DR; Muss HB; Richards F; Cooper MR; Stuart JJ; Pope EK; Spurr CL
    Am J Clin Oncol; 1983 Jun; 6(3):327-30. PubMed ID: 6303106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible enhancement of vincristine neuropathy by VP-16.
    Thant M; Hawley RJ; Smith MT; Cohen MH; Minna JD; Bunn PA; Ihde DC; West W; Matthews MJ
    Cancer; 1982 Mar; 49(5):859-64. PubMed ID: 6277454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association.
    Jackson DV; Zekan PJ; Caldwell RD; Slatkoff ML; Harding RW; Case LD; Hopkins JO; Muss HB; Richards F; White DR
    J Clin Oncol; 1984 Dec; 2(12):1343-51. PubMed ID: 6096517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
    Evans WK; Feld R; Murray N; Pater J; Shelley W; Willan A; Osoba D; Levitt M; Coy P; Hodson I
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):10-6. PubMed ID: 3020692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy in small cell lung carcinoma. A randomized study of two intensive regimens.
    Lowenbraun S; Birch R; Buchanan R; Krauss S; Durant J; Perez C; Mill W; Vollmer R; Ogden L
    Cancer; 1984 Dec; 54(11):2344-50. PubMed ID: 6093979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.
    Jett JR; Everson L; Therneau TM; Krook JE; Dalton RJ; Marschke RF; Veeder MH; Brunk SF; Mailliard JA; Twito DI
    J Clin Oncol; 1990 Jan; 8(1):33-8. PubMed ID: 2153193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer.
    Comis RL
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):40-4. PubMed ID: 3020699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial therapy with cisplatin plus VP-16 in small-cell lung cancer.
    Einhorn LH
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):5-9. PubMed ID: 3020701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer.
    Bunn PA; Greco FA; Einhorn L
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):45-53. PubMed ID: 3020700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
    Feld R; Evans WK; Coy P; Hodson I; MacDonald AS; Osoba D; Payne D; Shelley W; Pater JL
    J Clin Oncol; 1987 Sep; 5(9):1401-9. PubMed ID: 3040923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
    Einhorn LH; Crawford J; Birch R; Omura G; Johnson DH; Greco FA
    J Clin Oncol; 1988 Mar; 6(3):451-6. PubMed ID: 2832549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer.
    Everson LK; Jett JR; O'Fallon JR; Krook JE; Dalton RJ; Mailliard JA; Tschetter LK; Cullinan SA; Gerstner JB; Morton RF
    Am J Clin Oncol; 1989 Aug; 12(4):339-44. PubMed ID: 2547304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
    Johnson DH; Wolff SN; Hainsworth JD; Porter LL; Grosh WW; Hande KR; Greco FA
    J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.